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Abstract  
Vitiligo is an important skin disease of childhood, which may lead to deep psychological trauma, resulting in a 
poor quality of life and low self-esteem. The Authors discuss a short review of the more conventional therapies 
available for the treatment of vitiligo in children. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Vitiligo is an acquired, chronic, maybe 
autoimmune, pigmentary disorder characterised by 
white macules and patches, due to the progressive 
loss of cutaneous melanocytes and to an abnormality 
in their normal function [1]. 
Usually, it starts in childhood or young adult: it 
has been estimated that about 50% of patients 
develop vitiligo before the age of 20 years and about 
25% of them develop the disease before the age of 8, 
with a mean age of 4 - 5 years [2]. 
In pediatric age, vitiligo may represent a 
psychological trauma for both patients and their 
parents, resulting in emotional disorders (e.g. anxiety, 
depression), poor quality of life scores, and low self-
esteem [3]. 
Treating vitiligo and supporting patients to live 
their stigmatising condition, is the first aim of a 
dermatologist. Fortunately, nowadays different 
treatments, both medicals (Table 1) and surgical, are 
available. 
 
 
Topical treatments 
 
Topical corticosteroids (TCs) 
The efficacy of topical corticosteroids in the 
treatment of vitiligo, especially of localised forms on 
the face and other body’s area, is well - known since 
long time [4]. 
 
Table 1: Current traditional therapeutic options for vitiligo in 
children 
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Treatment modality Drugs Mechanism of 
actions 
Side effect 
Topical treatments Calcineurin 
inhibitors 
Immunomodulation Burning sensation, 
erythema, transient 
pruritus; risk of 
malignancies? 
 Calcipotriol Repigmentation, 
immunosuppression 
Transient burning or 
irritation 
 Corticosteroids Immunomodulation Epidermal atrophy. 
striae, telangiectasia, 
glaucoma, 
tachyphylaxis, 
hypothalamus-
pituitary axis 
suppression, 
Cushing's syndrome, 
growth retardation 
Systemic 
treatments 
Corticosteroids Immunomodulation Glaucoma, 
tachyphylaxis, 
hypothalamus-
pituitary axis 
suppression, 
Cushing's syndrome, 
growth retardation 
Phototherapies PUVA (12yo), 
Topical PUVA, 
Topical PUVA sol, 
nbUVB 
Repigmentation, 
immunomodulation 
Erythema, itching or 
burning sensation; 
chronic actinic 
damage; psoralen 
toxicity               
(nausea, vomiting, 
abdominal pain, liver 
toxicity, cataracts) 
Other therapeutic options: 
Combined therapies Camouflage 
Depigmentation therapy (monobenzyl ether of hydroquinone) 
Cognitive therapy and psychological support 
 
Steroids act as anti-inflammatory and 
immunosuppressant agents. Even if different classes 
of steroids are now available, the mid-  potent ones 
(e.g. betamethasone dipropionate 0.05% cream, 
0.05% clobetasol propionate ointment) are usually 
preferred for the treatment of young patients. The 
drugs may be applied once or twice a day, in 
consecutive or on alternate days. Different studies 
report a response rate of 45 - 60% in childhood 
vitiligo, with best outcome in inflammatory vitiligo [5]. 
Even if their use should be prolonged for 
several months, TCs are quite safe only if used for 
few weeks, not more than 2 - 4 months, to avoid local 
side effects (e.g. atrophy, striae, telangiectasia, 
hypertrichosis, acneiform eruption) and systemic ones 
due to the percutaneous absorption (e.g. 
tachyphylaxis, suppression of hypothalamic-pituitary-
adrenal axis, Cushing's syndrome and growth 
retardation). In detail, the use of TCs on vitiligo 
patches of the face should be avoided or limited in 
time because of the higher risk of topical side effects, 
including glaucoma [6][7]. 
 
Topical calcineurin inhibitors (TCI) 
Topical calcineurin inhibitors (tacrolimus and 
pimecrolimus) are considered valid alternatives to TCs 
for the treatment of localised forms of vitiligo. They act 
as immunomodulator agents: by blocking calcineurin, 
they inhibit the cytokines expression [8]. 
As TCs, TCIs are indicated for the treatment 
of localised forms of vitiligo, also for the facial lesions 
where they seem to be safer than steroids. Usually, 
TCIs are prescribed twice a day. 
Tacrolimus 0.1% seems to be more effective 
than pimecrolimus 1%, achieving a repigmentation 
rate similar to that of topical clobetasol propionate 
(0.05%) [9]. Pimecrolimus 1% is another valid option 
for the treatment of facial lesions, especially on the 
thinnest cutaneous areas, such as eyelids [10]. 
Usually, TCIs are safe and well tolerated. The 
most common side effects are burning sensation, 
transient pruritus and erythema at the side of the 
application. Because of the potential risk of 
malignancies (e.g. skin cancers and lymphoma), TCIs 
cannot be used in children < 2 years. The major limit 
to treat vitiligo with CIs is due to their costs [6]. 
 
Calcipotriol 
Calcipotriol is a synthetic vitamin D3 
analogue, which has been used for many years in the 
treatment of psoriasis for its ability to regulate the 
epidermal turnover. 
Its use in vitiligo patients, start with the 
observations that its topical application, on psoriatic 
lesions, may cause perilesional hyperpigmentation. 
Even if the exact mechanism of action has to be 
elucidated, calcipotriol seems to stimulate 
melanogenesis and to halt the melanocytes 
destruction by T - cells [11]. 
Calcipotriol is applied once a day. It seems to 
be less effective than TCs, with variable results in 
term of repigmentation rate. Interesting, calcipotriol 
seems to stimulate repigmentation in both treated and 
untreated skin, and to continue its action also after 
treatment termination, leading to hypothesise a 
systemic effect of the drug applied topically [12]. 
The drug is well tolerated, and the most 
common side effects are represented by a transient 
burning sensation or irritation at the site of application. 
The treated sites should not be exposed to 
phototherapy to avoid cutaneous hyperpigmentation. 
 
 
Systemic treatment 
 
Systemic corticosteroids (SCs) 
In patients affected by unstable vitiligo, 
another therapeutic option is the systemic 
administration of corticosteroids (e.g. betamethasone, 
methylprednisolone), which seem to be useful to stop 
the progression of the disease and to induce 
repigmentation. Due to the potential well-described 
side effects, SCs are usually administered for a short 
period or in pulsed a regimen [13][14]. The dosages of 
SCs are usually decided by the patient's 
characteristics. Recently, an oral mini-pulse therapy 
(OMP) has been proposed [15]. It consists of the 
morning intake of betamethasone (0.1 mg/kg body 
weight) on two consecutive days in a week for 12 
weeks. After that, patients have to assume 1 
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mg/month for the following three months. The clinical 
results seem to be good, with minimal risk of side 
effects. 
 
 
Phototherapies 
 
Ultraviolet radiations (UVR), both in the range 
of UVB and UVA, are considered as a first line 
therapy especially for extensive vitiligo, because of 
their good efficacy and tolerance. The effects of UVR 
are both immunosuppression and stimulation of the 
melanocytes activity [16]. 
Today, a range of phototherapies are now 
available: oral PUVA; topical cream PUVA, bath 
PUVA; PUVA sol; narrow-band UVB. Broad band 
UVB should no longer be used because of the 
sunburn risk and low efficacy. 
 
PUVA therapy 
PUVA therapy consists of the oral intake of a 
photosensitizing psoralen (e.g. 8 - methoxypsoralen, 5 
-  methoxysporalen or 4, 5, 8 - trimethylpsoralen) 
followed by exposure to photoactivating UVA light 
(320 - 400 nm). Treatment is performed 2 - 3 times a 
week, increasing the dose of UVA on the base of 
patient’s response. Because of psoralen’s toxicity 
(e.g. gastric and ocular damage), PUVA therapy 
should not be performed in children < 12. The rate of 
repigmentation after oral PUVA is about 75% in 50-
60% of the children with vitiligo [4]. The possible side 
effects are due to both radiations and psoralens. 
While the most common short- time side effects are 
erythema, pruritus, xerosis and phototoxic reactions; 
the long-term ones include chronic actinic damage 
and carcinogenesis [16]. 
 
Topical PUVA 
A valid therapeutic option for children with 
vitiligo is the topical PUVA. It consists of the 
application of 0.1 - 0.01% 8-methoxypsoralen in 
hydrophilic petrolatum or ethanol onto the vitiligo skin, 
followed by exposure to UVA-irradiated with a dose of 
0.12 - 0.25 J/cm². The treatment is done 1 - 3 times a 
week, increasing the UVA dose until mild erythema 
will develop. The treatment provides good results, 
similar to the systemic PUVA [4]. The acute and 
chronic side effects, due to UV radiations, are well 
described. 
 
 
Topical PUVA sol 
Similar treatment is the topical PUVA sol: 
after the topical application of a psoralen cream, the 
patient will be exposed to sunlight. Although the 
proven efficacy of the treatment, the risk of acute and 
chronic actinic damage are well documented [17]. 
 
Bath PUVA 
Patients take a warm bath with 0.5 -1.0 mg/l 8 
- MOP for 20 min before they are exposed to UVA 
[18][19]. 
 
Narrow - band UVB (nb - UVB) 
Today, narrow-band UVB (nb - UVB, 311 nm) 
is considered a valid and safeness therapy for vitiligo, 
especially for children due to the lack of psoralens. It 
consists in the exposure to nb - UVB at the starting 
dose of 0.1 mJ/cm², followed by 20% increasing dose 
of UVR on a weekly basis, accordingly to the clinical 
response. Treatment is well - tolerated. The 
commonest acute side effects are pruritus and 
erythema. Apart from supposed photo-damages, long-
term side effects are yet to be determined [16]. 
Recent studies show how nb - UVB is more active 
than topical and oral PUVA, and that the 
repigmentation achieved with nb - UVB is more 
persistent and more similar to the colour of the 
unaffected skin [20]. 
 
Combined treatments 
In the last years, different types of combined 
therapies have been proposed for the treatment of 
vitiligo in children. 
Topical corticosteroids may be used in 
combination with calcipotriol [20]. This type of 
association seems to provide better clinical results in 
term of repigmentation and fast response, also in 
patients who did not have a response to the use of 
steroids alone. Moreover, the combination calcipotriol 
-corticosteroids reduce the side effects due to each 
drug, leading to a safer treatment. 
In progressive vitiligo, TCs may be associated 
to the oral ones [21]. Apart from the risks due to the 
steroids therapy, the protocol seems to be effective in 
halting the progression of the disease and in inducing 
skin repigmentation. Finally, a study underlines also 
how the combination of OMP to nb - UVB 
phototherapy should be superior in the treatment of 
unstable vitiligo, then the systemic corticosteroids 
used alone [22]. 
Topical treatments may also be associated to 
phototherapies. For example, many studies show how 
nb-UVB combined with different topical drugs (e.g. 
Corticosteroids, vitamin D analogues, tacrolimus, 
pimecrolimus, pseudocatalase) could be more efficacy 
than phototherapy alone [16][17][18][19][20] 
[21][22][23][24]. In case of a combination, both TCI 
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and vitamin D analogues should be used after UVB, 
never before to avoid risks such as hyperpigmentation 
or skin cancer. 
 
Cosmetic camouflage 
Due to the deep psychological impact of 
vitiligo, which risks representing a real stigma for 
patients, the camouflage of vitiliginous areas is often 
recommended [25]. Today many products are 
available. The ideal cosmetic is non - allergenic, 
colour matching, easy to apply and to remove, water 
resistant and cost-limited. 
 
Depigmentation therapy 
 Unresponsive, widespread vitiligo or 
universal forms may be addressed to a total 
depigmentation therapy with 20% monobenzyl ether 
of hydroquinone (MBEH) [26]. 
 
Cognitive therapy and psychological 
support 
Among the different type of vitiligo’s 
treatment, cognitive therapy and psychological 
support are strictly recommended for children with 
vitiligo and their parents, especially in the cases 
where it is clear the impact of the skin disease on their 
quality of life [27]. 
 
Surgical therapies 
Surgical therapies are not recommended in 
childhood vitiligo and must to be limited to patients 
with stable localised lesions, unresponsive to the 
more conventional therapies. Surgical techniques in 
young children have to be also avoided because of 
their natural body growth in which lesions tend to 
extends, and they're difficult to stand still in the post-
operative time [4][5][6]. 
Today, different types of surgical techniques 
are available (Table 2). Among them, the suction 
blister epidermal grafting (SBEG) is the best choice 
for childhood vitiligo. 
Table 2: Surgical therapies for childhood vitiligo 
Treatment modality Technique Mechanism of 
actions 
Side effect 
Surgical therapies Mini punch grafts, 
suction blister 
epidermal grafts 
(SBEG), thin 
Thiersch grafts, 
transplantation of 
epidermal cell 
suspension, cultured 
melanocyte 
suspension, and 
cultured epidermis, 
combined therapies 
Correction of the 
pigmentary disease 
Cost factor and time 
consumption; inability 
to treat large areas; 
risk of infections; 
transient 
hyperpigmentation 
of recipient or donor 
site; risk of Koebner 
phenomenon at the 
graft site 
 
Among the various surgical techniques, 
suction blister epidermal grafting (SBEG) has been 
found to be most convenient and effective for children 
and adolescents, with an excellent rate of 
repigmentation (> 75%) in over 80% of patients [28]. 
Face and lips obtain best results [29]. 
Other surgical procedures include mini punch 
grafts; thin Thiersch grafts; transplantation of 
epidermal cell suspension, cultured melanocyte 
suspension, and cultured epidermis. Finally, there is 
the possibility to combine surgical techniques with 
medical treatments. An excellent example is the 
microdermabrasion of cutaneous lesions, followed by 
the topical use of pimecrolimus 1% cream [30]. 
Apart for the normal problems due to an 
intervention (e.g. risk of infection), the major problems 
due to surgical vitiligo therapies are represented by 
the necessity of expert equipment, the cost and the 
time consumption. Treatments are not indicated in the 
case of large vitiliginous areas and/or in case of active 
vitiligo. Finally, there are the risks of transient 
hyperpigmentation of recipient or donor site, and of 
Koebner phenomenon at the graft site. 
 
 
Conclusions 
 
Vitiligo’s treatment has two main goals: the 
first one is to halt the disease progression; the second 
one is to induce the lesions’ repigmentation, achieving 
an acceptable cosmetic result. In the last years, 
several therapeutic options, both medical and 
surgical, have been proposed for vitiligo. The choice 
of the best therapy for childhood vitiligo is based on 
various factors, such as patient’s age, psychological 
condition and expectation, distribution and extension 
of skin lesions, type of vitiligo (stable or not), 
availability and cost of the therapeutic options. 
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